Aslam Shiraz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aslam Shiraz has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- John Doorbar
Department of Pathology, University of Cambridge, Cambridge CB2 1QP, UK
6 shared publications Heather Griffin
Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QP, UK
4 shared publications- Nagayasu Egawa
Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QP, UK
4 shared publications Robin Crawford
Department of Gynae-Oncology, Cambridge University Hospitals, Cambridge, CB2 0QQ, UK
3 shared publicationsHardeep Singh Mudhar
National Specialist Ophthalmic Pathology Service, Department of Histopathology, E-Floor, Royal Hallamshire Hospital, Glossop Rd, Sheffield, S10 2JF, UK
2 shared publicationsIan G. Rennie
Sheffield Ocular Oncology Service, Department of Ophthalmology, Royal Hallamshire Hospital, Glossop Rd, Sheffield, S10 2JF, UK
2 shared publications
Latest Publications
- Open Access
- 2 December 2022
- Published by AOSIS in Southern African Journal of Infectious Diseases
- Vol. 37 (1) , 9
The preference of women living with HIV for the HPV self-sampling of urine at a rural HIV clinic in Uganda
Background: Women living with HIV have a double risk of acquiring cervical cancer (CC) due to repeated human papilloma virus (HPV) infections resulting from reduced immunity, with CC screening being low at 46.7%. Objectives: To determine the factors associated with the preference for HPV self-sampling using urine as well as establish its feasibility among women living with HIV attending a rural HIV clinic in Uganda. Method: A cross-sectional study design using quantitative data collection methods was used at the HIV clinic, Luweero District Hospital, among 426 women aged between 30 and 65 years. Data were analysed using descriptive statistics and modified Poisson regression. Urine samples were analysed using a Liferiver high-risk HPV genotyping real-time polymerase chain reaction (PCR) kit to determine the prevalence of the 15 HPV subtypes. Cervical intraepithelial neoplasia 2 (CIN2) was determined by visual inspection under acetic acid (VIA) using the nurse-led approach. Results: Most women (296/426, 70%) preferred nurse-led screening. Preference for HPV self-sampling using urine was associated with older age (46–65 years) (adjusted prevalence risk ratios [aPRR] 1.59; 95% confidence interval [CI]: 1.13–2.24), history of sexually transmitted infections (aPRR 0.74: 95% CI: 0.55–0.98) and acquisition of CC information from the television (aPRR 1.48: 95% CI: 1.09–2.02). Approximately 97% (68/70) of women living with HIV tested HPV positive with one or more subtypes. The most prevalent subtype of HPV was HPV 58 (87.1%). Only one woman tested positive with VIA. Conclusion: Nurse-led CC screening is preferred among women living with HIV, and HPV self-sampling using urine is feasible at the HIV clinic. Therefore, educational programmes to reassure the masses about urine HPV self-sampling need to be designed. Contribution: This study’s findings provide early insights into the merits and demerits of the current HPV sample collection approaches. Hence, HPV testing should be tailored to routine HIV care in rural communities.
- 2 December 2022
- Published by AOSIS in Southern African Journal of Infectious Diseases
- Vol. 37 (1) , 9
Open AccessThe preference of women living with HIV for the HPV self-sampling of urine at a rural HIV clinic in Uganda
Background: Women living with HIV have a double risk of acquiring cervical cancer (CC) due to repeated human papilloma virus (HPV) infections resulting from reduced immunity, with CC screening being low at 46.7%. Objectives: To determine the factors associated with the preference for HPV self-sampling using urine as well as establish its feasibility among women living with HIV attending a rural HIV clinic in Uganda. Method: A cross-sectional study design using quantitative data collection methods was used at the HIV clinic, Luweero District Hospital, among 426 women aged between 30 and 65 years. Data were analysed using descriptive statistics and modified Poisson regression. Urine samples were analysed using a Liferiver high-risk HPV genotyping real-time polymerase chain reaction (PCR) kit to determine the prevalence of the 15 HPV subtypes. Cervical intraepithelial neoplasia 2 (CIN2) was determined by visual inspection under acetic acid (VIA) using the nurse-led approach. Results: Most women (296/426, 70%) preferred nurse-led screening. Preference for HPV self-sampling using urine was associated with older age (46–65 years) (adjusted prevalence risk ratios [aPRR] 1.59; 95% confidence interval [CI]: 1.13–2.24), history of sexually transmitted infections (aPRR 0.74: 95% CI: 0.55–0.98) and acquisition of CC information from the television (aPRR 1.48: 95% CI: 1.09–2.02). Approximately 97% (68/70) of women living with HIV tested HPV positive with one or more subtypes. The most prevalent subtype of HPV was HPV 58 (87.1%). Only one woman tested positive with VIA. Conclusion: Nurse-led CC screening is preferred among women living with HIV, and HPV self-sampling using urine is feasible at the HIV clinic. Therefore, educational programmes to reassure the masses about urine HPV self-sampling need to be designed. Contribution: This study’s findings provide early insights into the merits and demerits of the current HPV sample collection approaches. Hence, HPV testing should be tailored to routine HIV care in rural communities.
- Open Access
- 18 July 2022
- Published by Elsevier in EBioMedicine
- Vol. 82, 104157
Cervical cell lift: A novel triage method for the spatial mapping and grading of precancerous cervical lesions
- 18 July 2022
- Published by Elsevier in EBioMedicine
- Vol. 82, 104157
Open AccessCervical cell lift: A novel triage method for the spatial mapping and grading of precancerous cervical lesions
- Open Access
- 1 January 2021
- Published by Elsevier in EBioMedicine
- Vol. 63, 103177
Dynamics of papillomavirus in vivo disease formation & susceptibility to high-level disinfection—Implications for transmission in clinical settings
- 1 January 2021
- Published by Elsevier in EBioMedicine
- Vol. 63, 103177
Open AccessDynamics of papillomavirus in vivo disease formation & susceptibility to high-level disinfection—Implications for transmission in clinical settings
- Open Access
- 17 April 2020
- Published by Wiley in Cytopathology
- Vol. 31 (4) , 258-270
The early detection of cervical cancer. The current and changing landscape of cervical disease detection
Cervical cancer prevention has undergone dramatic changes over the past decade. With the introduction of human papillomavirus (HPV) vaccination, some countries have seen a dramatic decline in HPV‐mediated cervical disease. However, widespread implementation has been limited by economic considerations and the varying healthcare priorities of different countries, as well as by vaccine availability and, in some instances, vaccine hesitancy amongst the population/government. In this environment, it is clear that cervical screening will retain a critical role in the prevention of cervical cancer and will in due course need to adapt to the changing incidence of HPV‐associated neoplasia. Cervical screening has, for many years, been performed using Papanicolaou staining of cytology samples. As our understanding of the role of HPV in cervical cancer progression has advanced, and with the availability of sensitive detection systems, cervical screening now incorporates HPV testing. Although such tests improve disease detection, they are not specific, and cannot discriminate high‐grade from low‐grade disease. This has necessitated the development of effective triage approaches to stratify HPV‐positive women according to their risk of cancer progression. Although cytology triage remains the mainstay of screening, novel strategies under evaluation include DNA methylation, biomarker detection and the incorporation of artificial intelligence systems to detect cervical abnormalities. These tests, which can be partially anchored in a molecular understanding of HPV pathogenesis, will enhance the sensitivity of disease detection and improve patient outcomes. This review will provide insight on these innovative methodologies while explaining their scientific basis drawing from our understanding of HPV tumour biology.
- 17 April 2020
- Published by Wiley in Cytopathology
- Vol. 31 (4) , 258-270
Open AccessThe early detection of cervical cancer. The current and changing landscape of cervical disease detection
Cervical cancer prevention has undergone dramatic changes over the past decade. With the introduction of human papillomavirus (HPV) vaccination, some countries have seen a dramatic decline in HPV‐mediated cervical disease. However, widespread implementation has been limited by economic considerations and the varying healthcare priorities of different countries, as well as by vaccine availability and, in some instances, vaccine hesitancy amongst the population/government. In this environment, it is clear that cervical screening will retain a critical role in the prevention of cervical cancer and will in due course need to adapt to the changing incidence of HPV‐associated neoplasia. Cervical screening has, for many years, been performed using Papanicolaou staining of cytology samples. As our understanding of the role of HPV in cervical cancer progression has advanced, and with the availability of sensitive detection systems, cervical screening now incorporates HPV testing. Although such tests improve disease detection, they are not specific, and cannot discriminate high‐grade from low‐grade disease. This has necessitated the development of effective triage approaches to stratify HPV‐positive women according to their risk of cancer progression. Although cytology triage remains the mainstay of screening, novel strategies under evaluation include DNA methylation, biomarker detection and the incorporation of artificial intelligence systems to detect cervical abnormalities. These tests, which can be partially anchored in a molecular understanding of HPV pathogenesis, will enhance the sensitivity of disease detection and improve patient outcomes. This review will provide insight on these innovative methodologies while explaining their scientific basis drawing from our understanding of HPV tumour biology.
- Open Access
- 15 October 2019
- Published by Elsevier in Laboratory Investigation
- Vol. 33 (2) , 320-1
Correction to: Human papillomavirus type 16 causes a defined subset of conjunctival in situ squamous cell carcinomas
- 15 October 2019
- Published by Elsevier in Laboratory Investigation
- Vol. 33 (2) , 320-1
Open AccessCorrection to: Human papillomavirus type 16 causes a defined subset of conjunctival in situ squamous cell carcinomas
- 4 September 2019
- Published by Elsevier in Laboratory Investigation
- Vol. 33 (1) , 74-90
Human papillomavirus type 16 causes a defined subset of conjunctival in situ squamous cell carcinomas
- 4 September 2019
- Published by Elsevier in Laboratory Investigation
- Vol. 33 (1) , 74-90
Human papillomavirus type 16 causes a defined subset of conjunctival in situ squamous cell carcinomas
- 1 June 2017
- Published by Elsevier in Obstetrics, Gynaecology & Reproductive Medicine
- Vol. 27 (6) , 177-183
Colposcopy and cervical intraepithelial neoplasia
- 1 June 2017
- Published by Elsevier in Obstetrics, Gynaecology & Reproductive Medicine
- Vol. 27 (6) , 177-183
Colposcopy and cervical intraepithelial neoplasia